Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
Completed · Phase 1
Conditions studied: Atopic Dermatitis
In brief
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
Key facts
- Study ID
- NCT03826901
- Run by
- LEO Pharma
- People needed
- 46
- Starts
- 2019-02-20
- Expected to finish
- 2021-10-29
- Last updated by the study team
- 2025-02-24
Who can join
Age: 2 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- LEO Pharma investigational site — Birmingham, Alabama, United States
- LEO Pharma investigational site — Phoenix, Arizona, United States
- LEO Pharma investigational site — Fountain Valley, California, United States
- LEO Pharma investigational site — Irvine, California, United States
- LEO Pharma investigational site — Los Angeles, California, United States
- LEO Pharma investigational site — Centennial, Colorado, United States
- LEO Pharma investigational site — New Haven, Connecticut, United States
- LEO Pharma investigational site — Indianapolis, Indiana, United States
- LEO Pharma investigational site — Ypsilanti, Michigan, United States
- LEO Pharma investigational site — Tulsa, Oklahoma, United States
- LEO Pharma investigational site — Medford, Oregon, United States
- LEO Pharma investigational site — San Antonio, Texas, United States
- LEO Pharma investigational site — Red Deer, Alberta, Canada
- LEO Pharma investigational site — Hamilton, Ontario, Canada
- LEO Pharma investigational site — Montreal, Quebec, Canada
- LEO Pharma investigational site — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.